Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bazedoxifene Acetate

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,714Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 198481-33-3, Viviant, Bazedoxifene (acetate), Conbriza, Way-140424, Tse 424
    Molecular Formula
    C32H38N2O5
    Molecular Weight
    530.7  g/mol
    InChI Key
    OMZAMQFQZMUNTP-UHFFFAOYSA-N
    FDA UNII
    J70472UD3D
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
    2.1.2 InChI
    InChI=1S/C30H34N2O3.C2H4O2/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31;1-2(3)4/h6-15,20,33-34H,2-5,16-19,21H2,1H3;1H3,(H,3,4)
    2.1.3 InChI Key
    OMZAMQFQZMUNTP-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O.CC(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    J70472UD3D
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Bazedoxifene

    2. Tse 424

    3. Tse-424

    4. Tse424

    5. Way-140424

    2.3.2 Depositor-Supplied Synonyms

    1. 198481-33-3

    2. Viviant

    3. Bazedoxifene (acetate)

    4. Conbriza

    5. Way-140424

    6. Tse 424

    7. Duavive

    8. Bazedoxifen Acetate

    9. Way-tes 424

    10. J70472ud3d

    11. 198481-33-3 (acetate)

    12. 1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol Acetate

    13. Ncgc00182055-02

    14. Tse-424

    15. Bazedoxifene Acetate

    16. Dsstox_cid_28583

    17. Dsstox_rid_82854

    18. Dsstox_gsid_48657

    19. 1-(p-(2-(hexahydro-1h-azepin-1-yl)ethoxy)benzyl)-2-(p-hydroxyphenyl)-3-methylindol-5-ol Monoacetate (salt)

    20. 1-[[4-[2-(hexahydro-1h-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol Acetate

    21. 1h-indol-5-ol, 1-((4-(2-(hexahydro-1h-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-, Monoacetate (salt)

    22. 1-(p-(2-(hexahydro-1h-azepin-1-yl)ethoxy)benzyl)-2-(p-hydroxyphenyl)-3-methylindol-5-ol Acetic Acid

    23. Acetic Acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol

    24. Cas-198481-33-3

    25. Brilence

    26. Unii-j70472ud3d

    27. Bazedoxifene Acetate [usan]

    28. 1-{4-[2-(azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol Acetate

    29. Bazedoxifene Acetate [usan:jan]

    30. Bazedoxifene-acetate

    31. Viviant (tn)

    32. 1133695-49-4

    33. Bazedoxifeneacetate

    34. Schembl635726

    35. Chembl2106615

    36. Dtxsid3048657

    37. Bazedoxifene Acetate [mi]

    38. Bazedoxifene Acetate (jan/usan)

    39. Bazedoxifene Acetate [jan]

    40. Bazedoxifene Acetate [usan]

    41. Amy12155

    42. Bcp19656

    43. Ex-a5414

    44. Hy-a0036

    45. Tse 424;way-tes 424

    46. Tox21_113013

    47. Ac-099

    48. Bazedoxifene Acetate [mart.]

    49. Mfcd09260074

    50. S2167

    51. Bazedoxifene Acetate [who-dd]

    52. Akos015896590

    53. Tox21_113013_1

    54. Ccg-269916

    55. Ncgc00182055-03

    56. As-19563

    57. Bazedoxifene Acetate [orange Book]

    58. Ft-0660250

    59. Ft-0662499

    60. D03062

    61. Q27281282

    62. 1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-olacetate

    63. 1-(p-(2-(hexahydro-1h-azepin-1-yl)ethoxy)benzyl)-2-(p-hydroxyphenyl)-3-methylindol-5-ol Monoacetate (salt)

    64. 1h-indol-5-ol, 1-((4-(2-(hexahydro-1h-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-, Monoacetate (salt)

    2.4 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 530.7 g/mol
    Molecular Formula C32H38N2O5
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count7
    Exact Mass530.27807232 g/mol
    Monoisotopic Mass530.27807232 g/mol
    Topological Polar Surface Area95.2 Ų
    Heavy Atom Count39
    Formal Charge0
    Complexity654
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.

    When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

    Duavive is indicated for:

    - Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.

    The experience treating women older than 65 years is limited.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Selective Estrogen Receptor Modulators

    A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)

    Bone Density Conservation Agents

    Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)

    5.2 ATC Code

    G03XC02

    G03CC07